Chase, A., Schwaab, J., Hofmann, W., & Reiter, A. (2013). Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica, the hematology journal, 98(3), .
Chicago Style (17th ed.) CitationChase, Andrew, Juliana Schwaab, Wolf-Karsten Hofmann, and Andreas Reiter. "Ruxolitinib as Potential Targeted Therapy for Patients with JAK2 Rearrangements." Haematologica, the Hematology Journal 98, no. 3 (2013).
MLA (9th ed.) CitationChase, Andrew, et al. "Ruxolitinib as Potential Targeted Therapy for Patients with JAK2 Rearrangements." Haematologica, the Hematology Journal, vol. 98, no. 3, 2013.
Warning: These citations may not always be 100% accurate.